Travere director sells 20K shares after exercise
A Travere Therapeutics director exercised vested stock options for 20,000 shares and sold an equal number of shares under a pre-arranged Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Travere Therapeutics, Inc. (TVTX) director Jeffrey A. Meckler reported option exercises and related share sales on September 10, 2026. He exercised stock options for 10,000 shares at $17.44 and 10,000 shares at $26.52, receiving a total of 20,000 shares of common stock.
On the same date, he sold 20,000 shares of common stock in market transactions, split into four tranches of 1,700; 1,200; 14,000; and 3,100 shares at weighted average prices of $65.3917, $66.15, $67.4634, and $68.088, respectively. These sales were made under a Rule 10b5-1(c) trading plan adopted on June 11, 2026, and involved shares underlying fully vested options expiring in 2027 and 2028.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 20,000 shares ($907K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Meckler Jeffrey A
Role
Director
Sold
20,000 shs ($1.35M)
Approx. gross sale proceeds
$1.35M
Approx. exercise cost
$440K
Approx. pre-tax spread
$907K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F6 | 10,000 | $0.00 | $0.00 |
| Exercise | Stock option (right to buy) F6 | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $17.44 | $174K |
| Exercise | Common Stock | 10,000 | $26.52 | $265K |
| Sale | Common Stock F1, F2 | 1,700 | $65.3917 | $111K |
| Sale | Common Stock F1, F3 | 1,200 | $66.15 | $79K |
| Sale | Common Stock F1, F4 | 14,000 | $67.4634 | $944K |
| Sale | Common Stock F1, F5 | 3,100 | $68.088 | $211K |
Holdings After Transaction:
Stock option (right to buy) — 0 contracts (Direct);
Common Stock — 91,500 shares (Direct)
Footnotes (6)
- F1. This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.
- F2. The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3. The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4. The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5. The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F6. The stock option is fully vested and exercisable.
Key Figures
Options exercised at $17.44: 10,000 shares
Options exercised at $26.52: 10,000 shares
Total shares sold: 20,000 shares
+5 more
8 metrics
Options exercised at $17.44
10,000 shares
Stock options exercised for common stock on September 10, 2026 at $17.44 per share
Options exercised at $26.52
10,000 shares
Stock options exercised for common stock on September 10, 2026 at $26.52 per share
Total shares sold
20,000 shares
Common stock sold in four tranches on September 10, 2026
Weighted average sale price tranche 1
$65.3917 per share
1,700 shares sold on September 10, 2026; price range $64.835–$65.81
Weighted average sale price tranche 2
$66.15 per share
1,200 shares sold on September 10, 2026; price range $65.93–$66.74
Weighted average sale price tranche 3
$67.4634 per share
14,000 shares sold on September 10, 2026; price range $66.93–$67.92
Weighted average sale price tranche 4
$68.088 per share
3,100 shares sold on September 10, 2026; price range $67.94–$68.23
Rule 10b5-1 plan adoption date
June 11, 2026
Date the written trading plan governing these sales was adopted
Key Terms
Rule 10b5-1(c), weighted average sale price, stock option, fully vested and exercisable
4 terms
Rule 10b5-1(c) regulatory
"plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $65.3917"
stock option financial
"consists of the sale of shares underlying stock options granted to the Reporting Person"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
fully vested and exercisable financial
"The stock option is fully vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Travere Therapeutics (TVTX) report for Jeffrey A. Meckler?
Jeffrey A. Meckler exercised stock options for 20,000 shares of Travere Therapeutics common stock and sold 20,000 shares in market transactions on September 10, 2026, as disclosed in the Form 4.
What stock options did the Travere Therapeutics (TVTX) director exercise?
He exercised two fully vested stock option grants covering 10,000 shares at $17.44 per share and 10,000 shares at $26.52 per share. The options were originally granted on May 17, 2017 and May 9, 2018, expiring on May 17, 2027 and May 9, 2028, respectively.
Were the Travere Therapeutics (TVTX) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the sales were made pursuant to a written plan adopted on June 11, 2026 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
Is there information on the price ranges for the Travere Therapeutics (TVTX) insider sales?
Yes. The filing reports weighted average prices with ranges: $64.835–$65.81, $65.93–$66.74, $66.93–$67.92, and $67.94–$68.23. It also notes that full price-by-share details will be provided upon request.
Were the Travere Therapeutics (TVTX) stock options fully vested at exercise?
Yes. A footnote states that the stock options exercised by the director were fully vested and exercisable at the time of the reported transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
